Patent application number | Description | Published |
20120129152 | Diagnostic method for the prediction of the development of and control over the effectiveness of treatment of cardiovascular illnesses - A diagnostic method for the prediction of the development and control of the effectiveness of the treatment of cardiovascular diseases, in which patient tissue samples are taken, microassay are prepared, specific antiviral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: when the number of cells infected by cytomegalovirus and any other viruses decreases by more than 50±10% in patients without symptoms of cardiovascular pathology, a diagnostic conclusion is high danger of the development of atherosclerosis; if the number of cells infected by cytomegalovirus and any other viruses exceeds 50±10% in patients with demonstrated clinical signs of cardiovascular system pathology, a diagnostic conclusion is drawn of the danger of the development of complications such as arrhythmia, thrombolytic embolism. | 05-24-2012 |
20120129153 | Diagnostic method for the prediction of the development and control of the effectiveness of the treatment of oncological illnesses - A diagnostic method, in which patient tissue samples are taken, microassay are prepared, specific anti-viral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: if the number of blood cells infected by any two or more viruses exceeds 50±10% in patients without signs of oncological pathology, a diagnostic conclusion is drawn of a high danger of oncological illness in connection with immune system ineffectiveness; if the number of cells infected by any two or more viruses exceeds 50±10% in patients with diagnosed oncological illnesses, a diagnostic conclusion of the cancer tumor's low sensitivity to chemotherapy and the perspective of quick tumor metastasis is drawn. | 05-24-2012 |
20120129195 | Method of quick laboratory diagnosis if illnesses based on the discovery of specific proteins and equipment for its implementation - A method of quick laboratory diagnosis of diseases, based on the discovery of specific protein targets characteristic to the disease in the reaction of their specific interaction with other protein reagents, distinct in that specific protein targets for the given disease are hydrolyzed with proteolytic enzymes and then the chemical structure of the oligopeptide formula created is modified in such a way that its charge is changed to the opposite. This method of quick laboratory diagnosis of illnesses based on the discovery of specific proteins, and the equipment for its implementation, may be applied for the discovery of viral and microbial antigens in various human biological fluids. The method may also be used for the detection of new and little-studied infectious diseases in connection with the ease of diagnostic preparation. | 05-24-2012 |
20120129760 | Modified peptides with antiviral properties and methods for obtaining them - This invention may be used in human and veterinary medicine for the creation of a drug that is effective perorally in the treatment of many viral infections, such as influenza, herpes, and cytomegalovirus. | 05-24-2012 |
20120129787 | Modified oligopeptides with anticancer properties and methods of obtaining them - This invention may be used in human and veterinary medicine for the creation of a drug that is effective perorally in the treatment of oncological illnesses. | 05-24-2012 |
20120130060 | Modified antisense oligopeptides with anticancer properties and method of obtaining them - This invention may be used in human and veterinary medicine for the creation of a drug that is effective in the treatment of oncological illnesses in animals and humans. | 05-24-2012 |
20120130699 | Method of molecular design and synthesis of therapeutic and preventive drugs - Industrial Application: This invention may be used in human and veterinary medicine for the design (creation and synthesis) of therapeutic and preventive drugs that are effective for the treatment of oncological and viral human and animal illnesses and for the design of new medicines. | 05-24-2012 |
20120195856 | Method of treating patients with cardiovascular illness - This invention may be used in human and veterinary medicine in combination with traditional methods of treatment of cardiovascular illnesses for the purpose of increasing their effectiveness. | 08-02-2012 |
20120195911 | Method of treatment of cancer patients - This invention may be used in human and veterinary medicine in combination with traditional methods of treatment of oncological illnesses for the purpose of increasing their effectiveness. | 08-02-2012 |
20120195925 | Vaccines with increased immunogenicity and methods for obtaining them - Vaccines with increased immunogenicity, distinct in that in the capacity of a specific immunogenic component, whole vaccine antigens or vaccine antigens that have been cut into oligomer fragments are used; the mixture (assembly) of oligomer fragments or whole antigen obtained is modified by changing its molecular charge to the opposite. | 08-02-2012 |
20120195945 | Cosmetological and pharmaceutical formulae for the rejuvenation and restoration of skin, including after surgical procedures - This invention is related to pharmacology and cosmetology and may be used in the capacity of a medicinal and cosmetic substance for skin anti-aging, scar reduction, treatment of post-operative peritoneal commissures, increasing the speed of post-operative tissue regeneration, and for the liquidation of cellulite. | 08-02-2012 |
20120196801 | Wound-healing, anti-ambustial, regenerating, and anti-viral pharmaceutical formula for local administration - The main active ingredients of the formula are papaverin, bendazol, and insulin. The drug may be produced in soft, liquid medicinal form or as an aerosol. | 08-02-2012 |
20120197003 | Modified oligopeptides for the treatment of pancreatitis, stomach ulcers, and other hyperenzymemias based on enzyme peptide inhibitors and methods for obtaining them - Modified oligopeptides for the treatment of pancreatitis, stomach ulcers, and other hyperenzymemias based on an enzyme peptide inhibitor where in the capacity of the main active ingredient, a mixture (assembly) of chemically modified oligopeptides are used that are products of autological hydrolysis of the same proteolytic enzymes of trypsin, chymotrypsin, and papain, with changes of their molecular charges to the opposite through acylation with succinic anhydride and alkylation by monochloracetic acid. | 08-02-2012 |
20130288230 | Method for identification of a natural biopolymer - The invention presents a method of identifying natural biopolymer—a protein, DNA, RNA in biological fluids and environmental objects, which is based only on the structure of the biopolymer and does not require pathogen genome sequencing, or animals vaccination by biopolymer-antigen. For this purpose the biopolymer itself is taken—a protein, DNA, or RNA, that is fragmented with enzyme to oligomer fragments—a mixture of oligopeptides, oligonucleotides DNA mixture, mixture of RNA oligonucleotides, without dividing the mixture into individual components, then carboxylation of structure in oligomer components is performed by acylation or alkylation. | 10-31-2013 |
20140220556 | Method of Design and Synthesis of a New Drug - A method of design and synthesis of a new drug. This invention may be used in human and veterinary medicine for the design of new drugs that are effective in the treatment of oncological and viral human and animal illnesses and for the design of new medicines. In the method a biopolymer target for the drug action is selected; then the quantity of nitrogen-containing positively charged groups available for modification is calculated. Biopolymer target may be cut into oligomer fragments. Some of calculated nitrogen-containing positively charged groups are substituted with negatively charged groups by combinatorial modification. The obtained supramolecular assemblies are used as drug for the biopolymer target. | 08-07-2014 |
20140309276 | Pharmaceutical Composition Comprising a Mixture of Carboxylated Oligonucleotides - The invention describes a pharmaceutical composition, comprising a mixture of carboxylated oligonucleotides, obtained by hydrolysis of natural polynucleotides, that results in oligonucleotide mixture, and carboxylation of purine nucleotide bases in the oligonucleotide mixture. The oligonucleotide mixture (DNA, RNA, or a combination of the two) of plant, animal, or fungal origin is conducted through chemical or biochemical enzymatic procedures, and then, a chemical modification of the oligonucleotides is provided, with carboxylation of their purine nucleotide bases through alkylation with monochloroacetic acid, or acylation with succinic anhydride. The pharmaceutical composition may be used in humans and animals for cancer treatment, immunodeficiency, viral infection diseases, etc. | 10-16-2014 |
20150072929 | Pharmaceutical composition comprising a mixture of carboxylated oligopeptides - A pharmaceutical composition comprising a mixture of carboxylated oligopeptides, derived by hydrolysis of eukaryotic or prokaryotic cells and their subsequent partial carboxylation through acylation or alkylation of the amino acid and basic amino acid residues in the amino terminal structure of the oligopeptides. The resulting pharmaceutical composition can be used in production of medical drugs effective in the treatment of cancer, pancreatitis, viral infection, for the development of vaccines. | 03-12-2015 |
Patent application number | Description | Published |
20080213062 | CONSTANT LOAD FASTENER - Described herein are fasteners and devices for securing together several components so that the load applied to the components is constant or nearly constant. The fasteners described herein include a hyperelastic member having first end to which a first retainer is coupled and a second end to which a second retainer is coupled. The retainers are configured to contact the structures being fastened and transfer the load from the structures to the hyperelastic member. The hyperelastic member may be an elongate shaft (e.g., a rod, cylinder, strut, etc.), and is a shape memory alloy that is typically fabricated as a single crystal. | 09-04-2008 |
20090095493 | FRANGIBLE SHAPE MEMORY ALLOY FIRE SPRINKLER VALVE ACTUATOR - A temperature-activated valve for a conventional fire sprinkler utilizing a hyperelastic single-crystal shape memory alloy is described. The shape-memory element expands as it is heated, forcing a bolt to break, thereby opening the sprinkler valve. The devices described are less susceptible to accidental breakage than conventional actuators, and have fewer moving parts. Transition temperature of the shape memory alloy can be tuned to a narrow range. | 04-16-2009 |
20090139613 | HYPERELASTIC SHAPE SETTING DEVICES AND FABRICATION METHODS - Shape-setting methods for fabricating devices made of single crystal shape memory alloys. The method include drawing a single crystal of a shape memory alloy from a melt of the alloy. This is followed by heating and quenching the crystal sufficiently rapid to limit the formation of alloy precipitates to an amount which retains hyperelastic composition and properties of the crystal. | 06-04-2009 |
20090171294 | Single crystal shape memory alloy devices and methods - Devices and methods of making devices having one or more components made of single crystal shape memory alloy capable of large recoverable distortions, defined herein as “hyperelastic” SMA. Recoverable Strains are as large as 9 percent, and in special circumstances as large as 22 percent. Hyperelastic SMAs exhibit no creep or gradual change during repeated cycling because there are no crystal boundaries. Hyperelastic properties are inherent in the single crystal as formed: no cold work or special heat treatment is necessary. Alloy components are Cu—Al—X where X may be Ni, Fe, Co, Mn. Single crystals are pulled from melt as in the Stepanov method and quenched by rapid cooling to prevent selective precipitation of individual elemental components. Conventional methods of finishing are used: milling, turning, electro-discharge machining, abrasion. Fields of application include aerospace, military, automotive, medical devices, microelectronics, and consumer products. | 07-02-2009 |
20100006304 | SPRINKLER VALVE WITH ACTIVE ACTUATION - A temperature-activated valve for a conventional fire sprinkler utilizing a hyperelastic single-crystal shape memory alloy is described. The shape-memory element expands as it is heated, forcing a bolt to break, thereby opening the sprinkler valve. The shape memory element typically communicates with the valve so as to force it open. The devices described are less susceptible to accidental breakage than conventional actuators, and have fewer moving parts. Transition temperature of the shape memory alloy can be tuned to a narrow range. | 01-14-2010 |
Patent application number | Description | Published |
20110240959 | NANOSTRUCTURED DEVICE - A nanostructured device according to the invention comprises a first group of nanowires protruding from a substrate where each nanowire of the first group of nanowires comprises at least one pn- or p-i-n-junction. A first contact, at least partially encloses and is electrically connected to a first side of the pn- or p-i-n-junction of each nanowire in the first group of nanowires. A second contacting means comprises a second group of nanowires that protrudes from the substrate, and is arranged to provide an electrical connection to a second side of the pn- or p-i-n-junction. | 10-06-2011 |
20110254034 | NANOSTRUCTURED LED - The device according to the invention comprises a nanostructured LED with a first group of nanowires protruding from a first area of a substrate and a contacting means in a second area of the substrate. Each nanowire of the first group of nanowires comprises a p-i-n junction and a top portion of each nanowire or at least one selection of nanowires is covered with a light-reflecting contact layer. The contacting means of the second area is in electrical contact with the bottom of the nanowires, the light-reflecting contact layer being in electrical contact with the contacting means of the second area via the p-i-n junction. Thus when a voltage is applied between the contacting means of the second area and the light-reflecting contact layer, light is generated within the nanowire. On top of the light-reflecting contact layer, a first group of contact pads for flip-chip bonding can be provided, distributed and separated to equalize the voltage across the layer to reduce the average serial resistance. | 10-20-2011 |
20140239327 | NANOSTRUCTURED LED - The device according to the invention comprises a nanostructured LED with a first group of nanowires protruding from a first area of a substrate and a contacting means in a second area of the substrate. Each nanowire of the first group of nanowires comprises a p-i-n-junction and a top portion of each nanowire or at least one selection of nanowires is covered with a light reflecting contact layer. The contacting means of the second area is in electrical contact with the bottom of the nanowires, the light-reflecting contact layer being in electrical contact with the contacting means of the second area via the p-i-n-junction. Thus when a voltage is applied between the contacting means of the second area and the light-reflecting contact layer, light is generated within the nanowire. On top of the light-reflecting contact layer, a first group of contact pads for flip-chip bonding can be provided, distributed and separated to equalize the voltage across the layer to reduce the average serial resistance. | 08-28-2014 |
20140246650 | NANOSTRUCTURED DEVICE - A nanostructured device according to the invention comprises a first group of nanowires protruding from a substrate where each nanowire of the first group of nanowires comprises at least one pn- or p-i-n-junction. A first contact, at least partially encloses and is electrically connected to a first side of the pn- or p-i-n- junction of each nanowire in the first group of nanowires. A second contacting means comprises a second group of nanowires that protrudes from the substrate, and is arranged to provide an electrical connection to a second side of the pn- or p-i-n-junction. | 09-04-2014 |